- ISIN
- BMG762791017
- CUSIP
- 612657106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 1, 2021
Highlights
- Market Cap
- $19.60B
- Enterprise Value
- $18.18B
- EPS (TTM)
- -$0.44
- Total Revenue (TTM)
- $8.26M
- Gross Profit (TTM)
- $6.98M
- EBITDA (TTM)
- -$316.38M
- Year Range
- $10.71 - $32.79
- Target Price
- $33.20
- ROA (TTM)
- -5.25%
- ROE (TTM)
- -5.66%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ROIV Performance Chart
Roivant Sciences Ltd. (ROIV) is up 30.2% since the beginning of the year. At $28 per share, ROIV is trading 13.9% below its 52-week high of $33.
Loading charts...
Returns By Period
Roivant Sciences Ltd. (ROIV) has returned 30.18% so far this year and 152.91% over the past 12 months.
Roivant Sciences Ltd.
- 1D
- -2.89%
- 1M
- 1.51%
- YTD
- 30.18%
- 6M
- 40.55%
- 1Y
- 152.91%
- 3Y*
- 44.11%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
ROIV Monthly Returns History
Based on dividend-adjusted daily data since Oct 1, 2021, ROIV's average daily return is +0.17%, while the average monthly return is +3.34%. At this rate, an investment would double in approximately 1.8 years.
Historically, 54% of months were positive and 46% were negative. The best month was Oct 2022 with a return of +59.6%, while the worst month was Jan 2022 at -31.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.
On a daily basis, ROIV closed higher 49% of trading days. The best single day was Dec 1, 2021 with a return of +34.1%, while the worst single day was Oct 5, 2021 at -16.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.37% | 33.86% | -4.28% | 3.00% | 5.12% | -5.80% | 30.18% | ||||||
| 2025 | -5.92% | -3.50% | -6.05% | 15.16% | -5.42% | 2.55% | 0.80% | 5.02% | 26.82% | 32.12% | 4.10% | 4.28% | 83.43% |
| 2024 | -10.95% | 14.40% | -7.87% | 3.42% | -4.95% | 2.03% | 2.65% | 12.72% | -5.64% | 0.09% | 10.04% | -6.92% | 5.34% |
| 2023 | 3.88% | -2.53% | -8.78% | 15.85% | 6.32% | 10.89% | 18.85% | -3.42% | 0.95% | -26.03% | 10.65% | 17.47% | 40.55% |
| 2022 | -31.05% | -9.50% | -21.46% | -25.30% | 20.33% | -8.33% | -2.21% | -10.55% | -9.55% | 59.63% | 4.28% | 49.07% | -20.73% |
| 2021 | -15.08% | -16.50% | 52.04% | 7.81% |
Benchmark Metrics
Roivant Sciences Ltd. has an annualized alpha of 33.24%, beta of 0.96, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since October 04, 2021.
- This stock captured 164.29% of S&P 500 Index gains and 108.21% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 33.24%
- Beta
- 0.96
- R²
- 0.07
- Upside Capture
- 164.29%
- Downside Capture
- 108.21%
Return for Risk
Risk / Return Rank
ROIV ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Roivant Sciences Ltd. (ROIV) and compare them to S&P 500 Index.
| ROIV | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.73 | 2.39 | +1.34 |
Sortino ratioReturn per unit of downside risk | 5.42 | 3.25 | +2.17 |
Omega ratioGain probability vs. loss probability | 1.63 | 1.43 | +0.20 |
Calmar ratioReturn relative to maximum drawdown | 11.99 | 3.11 | +8.87 |
Martin ratioReturn relative to average drawdown | 39.15 | 14.38 | +24.77 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Roivant Sciences Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Roivant Sciences Ltd. was 79.22%, occurring on May 12, 2022. Recovery took 834 trading sessions.
The current Roivant Sciences Ltd. drawdown is 12.84%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -79.22%May 2022 | 4mo 22d | 3y 4mo | 3y 8moDec 2021 - Sep 2025 |
2021 bear market2021 | -37.33%Oct 2021 | 14d | 1mo 20d | 2mo 4dOct 2021 - Dec 2021 |
2021 bear market2021 | -20.04%Dec 2021 | 3d | 4d | 7dDec 2021 - Dec 2021 |
2026 correction2026 | -12.84%Jun 2026 | 12d | — | 13d 23hMay 2026 - now |
2026 correction2026 | -11.21%Feb 2026 | 21d | 1d | 22dJan 2026 - Feb 2026 |
Drawdown Indicators
| ROIV | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.22% | -56.78% | -22.44% |
Max Drawdown (1Y)Largest decline over 1 year | -12.84% | -9.10% | -3.74% |
Max Drawdown (3Y)Largest decline over 3 years | -36.47% | -18.90% | -17.57% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -12.84% | 0.00% | -12.84% |
Average DrawdownAverage peak-to-trough decline | -27.54% | -10.72% | -16.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.92% | 1.97% | +1.95% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Roivant Sciences Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Roivant Sciences Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ROIV relative to other companies in the Biotechnology industry. Currently, ROIV has a P/S ratio of 2,353.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ROIV in comparison with other companies in the Biotechnology industry. Currently, ROIV has a P/B value of 3.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ROIV
Add Roivant Sciences Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ROIV